Carcinogenicity risk associated with tacrolimus use in kidney transplant recipients: a systematic review and meta-analysis

BACKGROUND: Currently, tacrolimus is the preferred anti-rejection therapy for kidney transplant recipients due to its greater protection against acute rejections compared to cyclosporin A (CsA). Despite the advantages of kidney transplantation, it has been associated with an increased incidence of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liangping, Ma, Kuifen, Yao, Yao, Yu, Liang, Wu, Jianyong, Zhao, Qingwei, Ye, Ziqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984978/
https://www.ncbi.nlm.nih.gov/pubmed/35402193
http://dx.doi.org/10.21037/tau-22-138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984978/
https://www.ncbi.nlm.nih.gov/pubmed/35402193
http://dx.doi.org/10.21037/tau-22-138

Ejemplares similares